Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
J Invest Dermatol. 1990 Dec;95(6 Suppl):206S-208S.

Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma.

Author information

  • 1Department of Dermatology, Marselisborg Hospital, University of Aarhus, Denmark.


Eleven patients suffering from cutaneous T-cell lymphoma (mycosis fungoides) were treated with recombinant interferon alpha-2A in combination (seven patients) or alone. Two patients, one in combined treatment, went into clinical complete remission, and five experienced partial remission. Two patients progressed during therapy, and two were nonevaluable because they stopped treatment early due to side effects. Dosages of interferon were from 3 to 36 million units daily for 3 months, and thereafter 3 times weekly. Etretinate (0.7 mg/kg) was given orally. The study showed that recombinant interferon alpha-2A in combination with etretinate or alone can induce remission of cutaneous T-cell lymphoma.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk